DASH prediction score: Difference between revisions
Jump to navigation
Jump to search
(8 intermediate revisions by 2 users not shown) | |||
Line 9: | Line 9: | ||
==DASH Prediction Score== | ==DASH Prediction Score== | ||
* DASH Prediction Score was invented by A. Tosetto et al in 2012<ref name="TosettoIorio2012">{{cite journal|last1=Tosetto|first1=A.|last2=Iorio|first2=A.|last3=Marcucci|first3=M.|last4=Baglin|first4=T.|last5=Cushman|first5=M.|last6=Eichinger|first6=S.|last7=Palareti|first7=G.|last8=Poli|first8=D.|last9=Tait|first9=R. C.|last10=Douketis|first10=J.|title=Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)|journal=Journal of Thrombosis and Haemostasis|volume=10|issue=6|year=2012|pages=1019–1025|issn=15387933|doi=10.1111/j.1538-7836.2012.04735.x}}</ref>, and has been externally validated in subsequent study in 2017<ref name="TosettoTesta2017">{{cite journal|last1=Tosetto|first1=A.|last2=Testa|first2=S.|last3=Martinelli|first3=I.|last4=Poli|first4=D.|last5=Cosmi|first5=B.|last6=Lodigiani|first6=C.|last7=Ageno|first7=W.|last8=De Stefano|first8=V.|last9=Falanga|first9=A.|last10=Nichele|first10=I.|last11=Paoletti|first11=O.|last12=Bucciarelli|first12=P.|last13=Antonucci|first13=E.|last14=Legnani|first14=C.|last15=Banfi|first15=E.|last16=Dentali|first16=F.|last17=Bartolomei|first17=F.|last18=Barcella|first18=L.|last19=Palareti|first19=G.|title=External validation of the DASH prediction rule: a retrospective cohort study|journal=Journal of Thrombosis and Haemostasis|volume=15|issue=10|year=2017|pages=1963–1970|issn=15387933|doi=10.1111/jth.13781}}</ref> particularly in young adults. | |||
* DASH Prediction Score is a clinical prediction rule devised to assess the recurrence in patients with previous unprovoked venous thromboembolism especially in people aged <65 years.This helps decide whether anticoagulation be continued indefinitely or stopped after at least 3 months of anticoagulation.<ref name="pmid26316770">{{cite journal |vauthors=Fahrni J, Husmann M, Gretener SB, Keo HH |title=Assessing the risk of recurrent venous thromboembolism--a practical approach |journal=Vasc Health Risk Manag |volume=11 |issue= |pages=451–9 |date=2015 |pmid=26316770 |doi=10.2147/VHRM.S83718 |url=}}</ref> | |||
==DASH Prediction Score Calculator== | ==DASH Prediction Score Calculator== | ||
Line 26: | Line 20: | ||
==Interpretation== | ==Interpretation== | ||
* | * | ||
{| | {| | ||
|+ | |+ | ||
! rowspan="2" |Score | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Score | ||
! rowspan="2" |Annualized recurrence rate | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Annualized recurrence | ||
! colspan="3" |Cumulative recurrence rate | rate (%) | ||
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Cumulative recurrence rate(%) | |||
|- | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |1 year | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |2 year | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |5 year | |||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + | - 2 | |||
| style="background:#F5F5F5;" align="center" + |1.8 | |||
| style="background:#F5F5F5;" align="center" + |2.4 | |||
| style="background:#F5F5F5;" align="center" + |5.2 | |||
| style="background:#F5F5F5;" align="center" + |5.2 | |||
|- | |- | ||
| - | | style="background:#DCDCDC;" align="center" + | - 1 | ||
| | | style="background:#F5F5F5;" align="center" + |1.0 | ||
| | | style="background:#F5F5F5;" align="center" + |1.9 | ||
| | | style="background:#F5F5F5;" align="center" + |1.9 | ||
| | | style="background:#F5F5F5;" align="center" + |5.7 | ||
|- | |- | ||
| | | style="background:#DCDCDC;" align="center" + |0 | ||
| | | style="background:#F5F5F5;" align="center" + |2.4 | ||
| | | style="background:#F5F5F5;" align="center" + |4.2 | ||
| | | style="background:#F5F5F5;" align="center" + |5.4 | ||
| | | style="background:#F5F5F5;" align="center" + |9.5 | ||
|- | |- | ||
| | | style="background:#DCDCDC;" align="center" + |1 | ||
| | | style="background:#F5F5F5;" align="center" + |3.9 | ||
| | | style="background:#F5F5F5;" align="center" + |5.1 | ||
| | | style="background:#F5F5F5;" align="center" + |8.7 | ||
| | | style="background:#F5F5F5;" align="center" + |15.9 | ||
|- | |- | ||
| | | style="background:#DCDCDC;" align="center" + |2 | ||
| | | style="background:#F5F5F5;" align="center" + |6.3 | ||
| | | style="background:#F5F5F5;" align="center" + |8.4 | ||
| | | style="background:#F5F5F5;" align="center" + |12.8 | ||
| | | style="background:#F5F5F5;" align="center" + |25.3 | ||
|- | |- | ||
| | | style="background:#DCDCDC;" align="center" + |3 | ||
| | | style="background:#F5F5F5;" align="center" + |10.8 | ||
| | | style="background:#F5F5F5;" align="center" + |14.6 | ||
| | | style="background:#F5F5F5;" align="center" + |20.5 | ||
| | | style="background:#F5F5F5;" align="center" + |40.9 | ||
|- | |- | ||
| | | style="background:#DCDCDC;" align="center" + |4 | ||
| | | style="background:#F5F5F5;" align="center" + |19.9 | ||
| | | style="background:#F5F5F5;" align="center" + |21.9 | ||
| | | style="background:#F5F5F5;" align="center" + |33.6 | ||
| | | style="background:#F5F5F5;" align="center" + |61.3 | ||
|} | |} | ||
* Score – 2: annualized recurrence rate 1.8% | * Score – 2: annualized recurrence rate 1.8% |
Latest revision as of 13:49, 25 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: (insert your name here)
Synonyms and keywords: (add synonyms and create redirects)
Overview
[Name of the Score] is a (± validated) risk assessment tool designed to assess the (30-day/10-year/other timeframe) risk of (bleeding/ischemia/other end point) associated with (antiplatelet/antithrombotic/other treatment) among patients with (coronary heart disease/heart failure/other condition).
DASH Prediction Score
- DASH Prediction Score was invented by A. Tosetto et al in 2012[1], and has been externally validated in subsequent study in 2017[2] particularly in young adults.
- DASH Prediction Score is a clinical prediction rule devised to assess the recurrence in patients with previous unprovoked venous thromboembolism especially in people aged <65 years.This helps decide whether anticoagulation be continued indefinitely or stopped after at least 3 months of anticoagulation.[3]
DASH Prediction Score Calculator
Shown below is the calculator for DASH prediction score (check all the boxes that apply):
Interpretation
Score | Annualized recurrence
rate (%) |
Cumulative recurrence rate(%) | ||
---|---|---|---|---|
1 year | 2 year | 5 year | ||
- 2 | 1.8 | 2.4 | 5.2 | 5.2 |
- 1 | 1.0 | 1.9 | 1.9 | 5.7 |
0 | 2.4 | 4.2 | 5.4 | 9.5 |
1 | 3.9 | 5.1 | 8.7 | 15.9 |
2 | 6.3 | 8.4 | 12.8 | 25.3 |
3 | 10.8 | 14.6 | 20.5 | 40.9 |
4 | 19.9 | 21.9 | 33.6 | 61.3 |
- Score – 2: annualized recurrence rate 1.8%
- Score 2–3: intermediate-risk (1 to 5% mortality); consider treatment or hospitalization.
- Score ≥ 4: high-risk (> 5% mortality); treatment/hospitalization is warranted.
See also
- (Relevant score 1)
- (Relevant score 2)
- (Relevant score 3)
References
- ↑ Tosetto, A.; Iorio, A.; Marcucci, M.; Baglin, T.; Cushman, M.; Eichinger, S.; Palareti, G.; Poli, D.; Tait, R. C.; Douketis, J. (2012). "Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)". Journal of Thrombosis and Haemostasis. 10 (6): 1019–1025. doi:10.1111/j.1538-7836.2012.04735.x. ISSN 1538-7933.
- ↑ Tosetto, A.; Testa, S.; Martinelli, I.; Poli, D.; Cosmi, B.; Lodigiani, C.; Ageno, W.; De Stefano, V.; Falanga, A.; Nichele, I.; Paoletti, O.; Bucciarelli, P.; Antonucci, E.; Legnani, C.; Banfi, E.; Dentali, F.; Bartolomei, F.; Barcella, L.; Palareti, G. (2017). "External validation of the DASH prediction rule: a retrospective cohort study". Journal of Thrombosis and Haemostasis. 15 (10): 1963–1970. doi:10.1111/jth.13781. ISSN 1538-7933.
- ↑ Fahrni J, Husmann M, Gretener SB, Keo HH (2015). "Assessing the risk of recurrent venous thromboembolism--a practical approach". Vasc Health Risk Manag. 11: 451–9. doi:10.2147/VHRM.S83718. PMID 26316770.